Finished product reference
Children Cold
Tablet, Chewable · Oral · 80 mg/0.5 mg/7.5 mg
- List code
- 260
- Pharmacologic class
- Paediatric cold and flu combination preparation (category)
What it is and how it works
Products in this category typically combine an analgesic–antipyretic (usually paracetamol) with a sympathomimetic decongestant (e.g. pseudoephedrine or phenylephrine) and/or a sedating antihistamine (e.g. chlorphenamine), each acting on a different symptom of the common cold. They treat symptoms only and do not shorten the illness.
Indications
Short-term symptomatic relief of common cold and influenza-like symptoms in children, such as fever, aches, nasal congestion, rhinorrhoea and sneezing.
Contraindications
Children below the minimum age specified on the label (many authorities advise against cough and cold combination products under 6 years); concomitant MAO inhibitors or within 14 days of stopping them (for decongestant-containing products); hypersensitivity to components.
Warnings and precautions
Avoid concurrent use of other paracetamol-containing or decongestant products to prevent overdose; dose strictly according to age or weight. Antihistamines may cause drowsiness or paradoxical excitation, and decongestants may cause restlessness, tachycardia and insomnia. Seek medical advice if symptoms persist beyond a few days or high fever develops.
Storage and supply
Store below 25 °C, protected from moisture, out of the reach of children.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.